Cyberonics Will Promote VNS Direct To-Consumers For Depression
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics says it will conduct a cost-effectiveness study to supplement its 240-patient pivotal D02 trial of its VNS (vagus nerve stimulation) system for depression, which is expected to conclude in March 2002